About
BELKIN Vision is an Israeli medical device company founded in 2013, focused on innovative technologies for glaucoma treatment. The company has developed the Eagle™ device, which provides automated, contactless laser therapy known as Direct Selective Laser Trabeculoplasty (DSLT). This device is designed to enhance treatment accessibility for ophthalmologists, allowing for efficient and precise laser treatments directly to the eye's drainage system. BELKIN Vision aims to shift the paradigm of glaucoma care by promoting laser therapy as a first-line treatment alternative to traditional pharmaceutical drops. The company’s technology is intended to improve patient compliance and outcomes while expanding access to glaucoma care globally. In July 2024, BELKIN Vision was acquired by Alcon, integrating its DSLT technology into Alcon’s glaucoma portfolio and supporting the global adoption of this innovative treatment. The company is headquartered in Yavne, Israel, and employs around 37 people.
Technologies
Keywords
Company Information
- Employees18
- Founded2013
- Annual Revenue$5900000
- Total Funding$17800000
Location
Yavne, Center District, Israel
